← SynDRA
BMS-582949
SynDRA canonical compound SYN0024147 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
| Primary target(s) | MAPK14 | TNF |
| Mechanism of action | p38 MAPK inhibitor |
All known targets
Mechanisms of action (all sources)
- MAPK14 INHIBITOR
- MAP kinase p38 alpha inhibitor
Cross-references
Synonyms
- PS-540446
- BMS 582949
- UNII-CR743OME9E
- BMS582949
- CR743OME9E
- PS540446
- CHEMBL1230065
- PS 540446
- 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
- 3mvl
- SCHEMBL254996
- GTPL7838
- DTXSID90211380
- MolPort-044-560-326
- EX-A1265
- BCP14356
- ZINC36475284
- s8124
- BDBM50327009
- AKOS030573299
- DB12696
- Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-
- BMS582949 free base
- RefChem:120729
- DTXCID90133871
- MFCD18633248
- orb1300464
- SCHEMBL29554701
- BMS-582949 HCl?
- GLXC-15417
- YZA15217
- NSC800997
- BMS 582949 [WHO-DD]
- CCG-268724
- NSC-800997
- NCGC00507842-02
- AC-35395
- HY-14305
- PS540446; BMS582949 free base
Look up BMS-582949 in the interactive SynDRA portal →